Cardiotoxicity clinical trials at UC Cancer
2 research studies open to eligible people
open to eligible people ages 13-25
Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) is commonly given to treat pediatric cancer, and carries a risk of cardiotoxicity. Over the long term, children who receive these therapies have an increased risk of heart failure and early cardiovascular death. However, current strategies for identifying patients who are at risk prior to the development of significant changes in heart function are limited. This study will focus on imaging markers of cardiac injury and dysfunction with the goal of developing improved diagnostic tests and treatment strategies.
Experimental Treatment With "Carvedilol" to Avoid Heart Problems in Patients With HER-2-Positive Breast Cancer That Has Spread
“This study will test whether carvedilol can reduce heart problems during your cancer treatment.”
open to eligible people ages 18 years and up
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
at UC Davis